Search Results - therapeutics+%3e+immunology+and+immunotherapy

55 Results Sort By:
Improving Immunizations by Suppressing Autophagy in Cells (UCLA Case No. 2023-291)
UCLA researchers in the Department of Molecular, Cell and Developmental Biology have developed methods to suppress autophagy in cells to enhance immune response. These methods target local tumor sites instead of the whole body, thus reducing off-target effects and are applicable to a variety of cancer types, including solid and hematological tumors. BACKGROUND:...
Published: 7/8/2025   |   Inventor(s): Hilary Coller
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Hemodynamics Driven Magnetoelastic Vascular Graft (Case No. 2025-124)
Summary: UCLA researchers in the Department of Bioengineering have developed a novel magnetoelastic vascular graft to provide real-time, wireless, and continuous stenosis monitoring. TITLE: Hemodynamics Driven Magnetoelastic Vascular Graft Background: Vascular grafts are commonly used to restore blood flow in patients with blocked or damaged blood...
Published: 7/3/2025   |   Inventor(s): Jun Chen, Song Li, Guorui Chen
Keywords(s): cardiovascular monitoring, Diagnostic Platform Technologies (E.G. Microfluidics), hemodynamic monitoring, Hemodynamics, magnetoelastic sensor, Medical diagnostics, Vascular therapy
Category(s): Diagnostic Markers > Immunology, Life Science Research Tools > Screening Libraries, Medical Devices > Monitoring And Recording Systems, Therapeutics > Autoimmune, Therapeutics > Immunology And Immunotherapy, Therapeutics > Transplant, Therapeutics > Hematology, Therapeutics > Cardiovascular
Modified Hyaluronic Acid Hydrogels Containing Hyaluronidase for the Time‐Controlled and Targeted Release of anti-CTLA-4 and other Therapeutic Antibodies (UCLA Case No. 2016-526)
UCLA researchers from the Department of Medicine have developed a novel therapeutic platform for the administration of low-dose Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) antibody for cancer immunotherapy that synergizes with conventional PD-1 therapy while sparing systemic autoimmune toxicity. BACKGROUND: Immune checkpoint inhibitor (CPI)...
Published: 5/30/2025   |   Inventor(s): Michael Roth, Airi Harui
Keywords(s): Cancer Immunotherapy, Immunotherapy
Category(s): Platforms > Drug Delivery, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology
Gene Modifications to Enhance the Function of PSC-Derived T Cells and NK Cells (UCLA Case No. 2023-129)
UCLA researchers in the Department of Medicine have generated novel pluripotent stem cell derived T cells that exhibit improved survival, expansion, and anti-tumor efficacy for use in cell therapy treatments. BACKGROUND: The Food and Drug Administration has approved several chimeric antigen receptor-T (CAR-T) cell therapies since 2017 to combat lymphoma...
Published: 4/22/2025   |   Inventor(s): Christopher Seet
Keywords(s): CAR-T cell therapy, Immunotherapy, pluripotent stem cell (PSC), T-cell engineering
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Gene Therapy And Editing
Single-Chain Bispecific Chimeric Antigen Receptor Targeting BCMA and CS1 for the Treatment of Multiple Myeloma (UCLA Case No. 2018-680)
UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a single-chain bispecific chimeric antigen receptor targeting BCMA and CS1 for treating multiple myeloma. BACKGROUND: Multiple myeloma (MM) is a cancer of the plasma cells that accounts for over 30,000 new diagnoses each year, according to the American Cancer...
Published: 2/19/2025   |   Inventor(s): Yvonne Chen, Eugenia Zah
Keywords(s): Hematology, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines
Category(s): Life Science Research Tools, Therapeutics > Immunology And Immunotherapy, Therapeutics > Hematology
Gene Therapy for DOCK8 Deficiency (UCLA Case No. 2023-178)
UCLA researchers in the Department of Pediatrics Allergy and Immunology have developed a gene therapy method to express the full-length DOCK8 protein in cells, aimed at treating DOCK8 deficiency. These method allows for safe and effective DOCK8 expression in hematopoietic stem cells without the need for an HLA-matched donor, enabling patients to undergo...
Published: 2/18/2025   |   Inventor(s): Caroline Kuo
Keywords(s): bone marrow, bone marrow transplants, DOCK8, DOCK8 deficiency, Gene Editing Systems, Gene Therapy, hematopoietic stem cells, Immune System, immunodeficiency, Immunology, intein splicing
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Life Science Research Tools > Plasmids/Vectors
A Novel Lymphocyte Stimulation Assay To Quantify Immune Responses (UCLA Case No. 2022-079)
UCLA researchers in the Department of Medicine have developed lymphocyte stimulation assays to evaluate immune responses, supporting various clinical applications such as adjusting immunosuppressant drug levels and advancing COVID-19 vaccine development. The assay systems are reliable, cost-effective, and easy-to-perform, providing accurate assessments...
Published: 2/14/2025   |   Inventor(s): Yusaku Shino
Keywords(s): Antibody, biomarkers, cytokines, Immunity (Medical), immunosuppression, Organ Transplant
Category(s): Life Science Research Tools > Antibodies, Therapeutics > Immunology And Immunotherapy
An Alternative T Cell Redirecting Bispecific Antibody Against Human Cytomegalovirus (UCLA Case No. 2024-198)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have created a novel T cell redirecting bispecific antibody (TRBA) for treatment of cytomegalovirus (CMV) infection. BACKGROUND: The human cytomegalovirus (CMV) has a seroprevalence of about 60% in the USA and nearly 100% of the population in some parts of the world....
Published: 2/14/2025   |   Inventor(s): Otto Yang
Keywords(s): Anti-CD3 antibodies, Bispecific antibodies, CD8 T cells, Human cytomegalovirus (CMV), immunocompromised patients, Immunotherapy, Lymphocytes, T cell redirecting bispecific antibody (TRBA), Transplant, Viral infection
Category(s): Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy
Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)
UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...
Published: 2/14/2025   |   Inventor(s): Roger Lo
Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)
UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced immunotherapy efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...
Published: 2/14/2025   |   Inventor(s): Bin Liu, Steven Dubinett
Keywords(s): anti-tumor immunity, cell-based therapy, Immune checkpoint blockade, Immunotherapy, non-small cell lung cancer, treatment resistance, Tumor microenvironment, Vaccines
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Respiratory And Pulmonary
1 2 3 4 5 6